Literature DB >> 21035406

CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Kavya Rakhra1, Pavan Bachireddy, Tahera Zabuawala, Robert Zeiser, Liwen Xu, Andrew Kopelman, Alice C Fan, Qiwei Yang, Lior Braunstein, Erika Crosby, Sandra Ryeom, Dean W Felsher.   

Abstract

Oncogene addiction is thought to occur cell autonomously. Immune effectors are implicated in the initiation and restraint of tumorigenesis, but their role in oncogene inactivation-mediated tumor regression is unclear. Here, we show that an intact immune system, specifically CD4(+) T cells, is required for the induction of cellular senescence, shutdown of angiogenesis, and chemokine expression resulting in sustained tumor regression upon inactivation of the MYC or BCR-ABL oncogenes in mouse models of T cell acute lymphoblastic lymphoma and pro-B cell leukemia, respectively. Moreover, immune effectors knocked out for thrombospondins failed to induce sustained tumor regression. Hence, CD4(+) T cells are required for the remodeling of the tumor microenvironment through the expression of chemokines, such as thrombospondins, in order to elicit oncogene addiction.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21035406      PMCID: PMC2991103          DOI: 10.1016/j.ccr.2010.10.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  76 in total

Review 1.  Oncogene addiction.

Authors:  I Bernard Weinstein; Andrew Joe
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

2.  CD8 T cell help for innate antitumor immunity.

Authors:  Anil Shanker; Grégory Verdeil; Michel Buferne; Else-Marit Inderberg-Suso; Denis Puthier; Florence Joly; Catherine Nguyen; Lee Leserman; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 3.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 4.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy.

Authors:  Sreenath V Sharma; Jeffrey Settleman
Journal:  Genes Dev       Date:  2007-12-15       Impact factor: 11.361

Review 5.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.

Authors:  Paola Allavena; Antonio Sica; Graziella Solinas; Chiara Porta; Alberto Mantovani
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-29       Impact factor: 6.312

6.  Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis.

Authors:  Jeremy B Swann; Matthew D Vesely; Anabel Silva; Janelle Sharkey; Shizuo Akira; Robert D Schreiber; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

Review 7.  Thrombospondins in cancer.

Authors:  S Kazerounian; K O Yee; J Lawler
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

8.  Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.

Authors:  Laura Soucek; Elizabeth R Lawlor; Darya Soto; Ksenya Shchors; Lamorna Brown Swigart; Gerard I Evan
Journal:  Nat Med       Date:  2007-09-30       Impact factor: 53.440

9.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.

Authors:  Nadia Guerra; Ying Xim Tan; Nathalie T Joncker; Augustine Choy; Fermin Gallardo; Na Xiong; Susan Knoblaugh; Dragana Cado; Norman M Greenberg; Norman R Greenberg; David H Raulet
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

10.  Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer.

Authors:  Holbrook E Kohrt; Navid Nouri; Kent Nowels; Denise Johnson; Susan Holmes; Peter P Lee
Journal:  PLoS Med       Date:  2005-09-06       Impact factor: 11.069

View more
  160 in total

Review 1.  Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors:  Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal:  Cancer Discov       Date:  2014-11-13       Impact factor: 39.397

2.  Cancer: final act of senescence.

Authors:  Manuel Serrano
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

3.  New immune therapy targets tumor-associated environment: from bone marrow to tumor site.

Authors:  Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2011-12-12       Impact factor: 11.530

4.  Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

Authors:  Douglas W McMillin; Jake Delmore; Joseph M Negri; Matthew Vanneman; Shohei Koyama; Robert L Schlossman; Nikhil C Munshi; Jacob Laubach; Paul G Richardson; Glenn Dranoff; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

5.  Tumor immunology: CD4(+) T cell sponsor oncogene addicts.

Authors:  Kirsty Minton
Journal:  Nat Rev Immunol       Date:  2011-01       Impact factor: 53.106

Review 6.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

7.  Can antitumor immunity help to explain "oncogene addiction"?

Authors:  Nicholas P Restifo
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

8.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

Review 9.  Drug development in the era of precision medicine.

Authors:  Sarah A Dugger; Adam Platt; David B Goldstein
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 10.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.